NT113, A pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification

Yasuyuki Yoshida, Tomoko Ozawa, Tsun Wen Yao, Wang Shen, Dennis Brown, Andrew T. Parsa, Jeffrey J. Raizer, Shi Yuan Cheng, Alexander H. Stegh, Andrew P. Mazar, Francis J. Giles, Jann N Sarkaria, Nicholas Butowski, Theodore Nicolaides, C. David James

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

This report describes results from our analysis of the activity and biodistribution of a novel pan-ERBB inhibitor, NT113, when used in treating mice with intracranial glioblastoma (GBM) xenografts. Approaches used in this investigation include: bioluminescence imaging (BLI) for monitoring intracranial tumor growth and response to therapy; determination of survival benefit from treatment; analysis of tumor IHC reactivity for indication of treatment effect on proliferation and apoptotic response; Western blot analysis for determination of effects of treatment on ERBB and ERBB signaling mediator activation; and high-performance liquid chromatography for determination of NT113 concentration in tissue extracts from animals receiving oral administration of inhibitor. Our results show that NT113 is active against GBM xenografts in which wild-type EGFR or EGFRvIII is highly expressed. In experiments including lapatinib and/or erlotinib, NT113 treatment was associated with the most substantial improvement in survival, as well as the most substantial tumor growth inhibition, as indicated by BLI and IHC results. Western blot analysis results indicated that NT113 has inhibitory activity, both in vivo and in vitro, on ERBB family member phosphorylation, as well as on the phosphorylation of downstream signaling mediator Akt. Results from the analysis of animal tissues revealed significantly higher NT113 normal brain-to-plasma and intracranial tumor-to-plasma ratios for NT113, relative to erlotinib, indicating superior NT113 partitioning to intracranial tissue compartments. These data provide a strong rationale for the clinical investigation of NT113, a novel ERBB inhibitor, in treating patients with GBM.

Original languageEnglish (US)
Pages (from-to)2919-2929
Number of pages11
JournalMolecular Cancer Therapeutics
Volume13
Issue number12
DOIs
StatePublished - Dec 1 2014

Fingerprint

Penetrance
Glioblastoma
Heterografts
Brain
Growth
Neoplasms
Western Blotting
Phosphorylation
Therapeutics
Tissue Extracts
Survival
Oral Administration
High Pressure Liquid Chromatography
Erlotinib Hydrochloride

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

NT113, A pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification. / Yoshida, Yasuyuki; Ozawa, Tomoko; Yao, Tsun Wen; Shen, Wang; Brown, Dennis; Parsa, Andrew T.; Raizer, Jeffrey J.; Cheng, Shi Yuan; Stegh, Alexander H.; Mazar, Andrew P.; Giles, Francis J.; Sarkaria, Jann N; Butowski, Nicholas; Nicolaides, Theodore; James, C. David.

In: Molecular Cancer Therapeutics, Vol. 13, No. 12, 01.12.2014, p. 2919-2929.

Research output: Contribution to journalArticle

Yoshida, Y, Ozawa, T, Yao, TW, Shen, W, Brown, D, Parsa, AT, Raizer, JJ, Cheng, SY, Stegh, AH, Mazar, AP, Giles, FJ, Sarkaria, JN, Butowski, N, Nicolaides, T & James, CD 2014, 'NT113, A pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification', Molecular Cancer Therapeutics, vol. 13, no. 12, pp. 2919-2929. https://doi.org/10.1158/1535-7163.MCT-14-0306
Yoshida, Yasuyuki ; Ozawa, Tomoko ; Yao, Tsun Wen ; Shen, Wang ; Brown, Dennis ; Parsa, Andrew T. ; Raizer, Jeffrey J. ; Cheng, Shi Yuan ; Stegh, Alexander H. ; Mazar, Andrew P. ; Giles, Francis J. ; Sarkaria, Jann N ; Butowski, Nicholas ; Nicolaides, Theodore ; James, C. David. / NT113, A pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification. In: Molecular Cancer Therapeutics. 2014 ; Vol. 13, No. 12. pp. 2919-2929.
@article{db6aca2332d8430fafc80c719810bd60,
title = "NT113, A pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification",
abstract = "This report describes results from our analysis of the activity and biodistribution of a novel pan-ERBB inhibitor, NT113, when used in treating mice with intracranial glioblastoma (GBM) xenografts. Approaches used in this investigation include: bioluminescence imaging (BLI) for monitoring intracranial tumor growth and response to therapy; determination of survival benefit from treatment; analysis of tumor IHC reactivity for indication of treatment effect on proliferation and apoptotic response; Western blot analysis for determination of effects of treatment on ERBB and ERBB signaling mediator activation; and high-performance liquid chromatography for determination of NT113 concentration in tissue extracts from animals receiving oral administration of inhibitor. Our results show that NT113 is active against GBM xenografts in which wild-type EGFR or EGFRvIII is highly expressed. In experiments including lapatinib and/or erlotinib, NT113 treatment was associated with the most substantial improvement in survival, as well as the most substantial tumor growth inhibition, as indicated by BLI and IHC results. Western blot analysis results indicated that NT113 has inhibitory activity, both in vivo and in vitro, on ERBB family member phosphorylation, as well as on the phosphorylation of downstream signaling mediator Akt. Results from the analysis of animal tissues revealed significantly higher NT113 normal brain-to-plasma and intracranial tumor-to-plasma ratios for NT113, relative to erlotinib, indicating superior NT113 partitioning to intracranial tissue compartments. These data provide a strong rationale for the clinical investigation of NT113, a novel ERBB inhibitor, in treating patients with GBM.",
author = "Yasuyuki Yoshida and Tomoko Ozawa and Yao, {Tsun Wen} and Wang Shen and Dennis Brown and Parsa, {Andrew T.} and Raizer, {Jeffrey J.} and Cheng, {Shi Yuan} and Stegh, {Alexander H.} and Mazar, {Andrew P.} and Giles, {Francis J.} and Sarkaria, {Jann N} and Nicholas Butowski and Theodore Nicolaides and James, {C. David}",
year = "2014",
month = "12",
day = "1",
doi = "10.1158/1535-7163.MCT-14-0306",
language = "English (US)",
volume = "13",
pages = "2919--2929",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - NT113, A pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification

AU - Yoshida, Yasuyuki

AU - Ozawa, Tomoko

AU - Yao, Tsun Wen

AU - Shen, Wang

AU - Brown, Dennis

AU - Parsa, Andrew T.

AU - Raizer, Jeffrey J.

AU - Cheng, Shi Yuan

AU - Stegh, Alexander H.

AU - Mazar, Andrew P.

AU - Giles, Francis J.

AU - Sarkaria, Jann N

AU - Butowski, Nicholas

AU - Nicolaides, Theodore

AU - James, C. David

PY - 2014/12/1

Y1 - 2014/12/1

N2 - This report describes results from our analysis of the activity and biodistribution of a novel pan-ERBB inhibitor, NT113, when used in treating mice with intracranial glioblastoma (GBM) xenografts. Approaches used in this investigation include: bioluminescence imaging (BLI) for monitoring intracranial tumor growth and response to therapy; determination of survival benefit from treatment; analysis of tumor IHC reactivity for indication of treatment effect on proliferation and apoptotic response; Western blot analysis for determination of effects of treatment on ERBB and ERBB signaling mediator activation; and high-performance liquid chromatography for determination of NT113 concentration in tissue extracts from animals receiving oral administration of inhibitor. Our results show that NT113 is active against GBM xenografts in which wild-type EGFR or EGFRvIII is highly expressed. In experiments including lapatinib and/or erlotinib, NT113 treatment was associated with the most substantial improvement in survival, as well as the most substantial tumor growth inhibition, as indicated by BLI and IHC results. Western blot analysis results indicated that NT113 has inhibitory activity, both in vivo and in vitro, on ERBB family member phosphorylation, as well as on the phosphorylation of downstream signaling mediator Akt. Results from the analysis of animal tissues revealed significantly higher NT113 normal brain-to-plasma and intracranial tumor-to-plasma ratios for NT113, relative to erlotinib, indicating superior NT113 partitioning to intracranial tissue compartments. These data provide a strong rationale for the clinical investigation of NT113, a novel ERBB inhibitor, in treating patients with GBM.

AB - This report describes results from our analysis of the activity and biodistribution of a novel pan-ERBB inhibitor, NT113, when used in treating mice with intracranial glioblastoma (GBM) xenografts. Approaches used in this investigation include: bioluminescence imaging (BLI) for monitoring intracranial tumor growth and response to therapy; determination of survival benefit from treatment; analysis of tumor IHC reactivity for indication of treatment effect on proliferation and apoptotic response; Western blot analysis for determination of effects of treatment on ERBB and ERBB signaling mediator activation; and high-performance liquid chromatography for determination of NT113 concentration in tissue extracts from animals receiving oral administration of inhibitor. Our results show that NT113 is active against GBM xenografts in which wild-type EGFR or EGFRvIII is highly expressed. In experiments including lapatinib and/or erlotinib, NT113 treatment was associated with the most substantial improvement in survival, as well as the most substantial tumor growth inhibition, as indicated by BLI and IHC results. Western blot analysis results indicated that NT113 has inhibitory activity, both in vivo and in vitro, on ERBB family member phosphorylation, as well as on the phosphorylation of downstream signaling mediator Akt. Results from the analysis of animal tissues revealed significantly higher NT113 normal brain-to-plasma and intracranial tumor-to-plasma ratios for NT113, relative to erlotinib, indicating superior NT113 partitioning to intracranial tissue compartments. These data provide a strong rationale for the clinical investigation of NT113, a novel ERBB inhibitor, in treating patients with GBM.

UR - http://www.scopus.com/inward/record.url?scp=84917734689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84917734689&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-14-0306

DO - 10.1158/1535-7163.MCT-14-0306

M3 - Article

VL - 13

SP - 2919

EP - 2929

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 12

ER -